Physician profile
Nathan P Smith
NPI 1730527144
$3,569.44
in general payments reported to CMS, 2019-2025
26 companies · $917 in 2025
The $917 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $86.23 · 2022: $47.59 · 2023: $1,087 · 2024: $1,152 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Travel and Lodging: $102 · Education: $81.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.47 |
| Travel and Lodging | $101.70 |
| Education | $81.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $498.49 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $457.68 | 2019-2025 | |
| Lundbeck LLC | $352.91 | 2023-2025 | Vyepti |
| Novo Nordisk INC | $252.08 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $249.71 | 2022-2024 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $205.85 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $192.71 | 2023-2025 | Veozah |
| Abbott Laboratories | $181.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Pfizer INC. | $172.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.51 | 2023-2025 | |
| Lilly USA, LLC | $129.90 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.70 | 2023-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $97.13 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $93.42 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $67.25 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.33 | 2019 | |
| Vifor Pharma, INC. | $54.08 | 2019-2020 | |
| Intra-Sana Laboratories | $49.96 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Xeris Pharmaceuticals, INC. | $40.73 | 2024-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.17 | 2024-2025 | Caplyta |
| Melinta Therapeutics, LLC | $33.84 | 2019 | |
| Portola Pharmaceuticals, LLC | $21.46 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.23 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.76 | 2019 | |
| Cook Medical LLC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.